Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-methoxypsoralen + interferon
- Development stage
- Unknown
- Lead developer
- Valeant Pharmaceuticals
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This is a combination therapy consisting of 8-methoxypsoralen (also known as methoxsalen or 8-MOP), a photoactive psoralen compound, and an interferon (typically interferon alfa-2a). The regimen is primarily used in conjunction with extracorporeal photochemotherapy (ECP) for the treatment of cutaneous T-cell lymphoma (CTCL), particularly mycosis fungoides. In this protocol, oral 8-methoxypsoralen acts as a photosensitizer; after administration, blood is treated with ultraviolet A (UVA) light outside the body to induce DNA crosslinking and apoptosis in targeted lymphocytes. Interferon alfa-2a is administered subcutaneously to enhance immune modulation and antitumoral effects. This combination has demonstrated improved response rates compared to either agent alone in CTCL stage II patients[1][2]. The mechanism involves both direct cytotoxicity from DNA crosslinking by activated psoralen and immunomodulation via cytokine signaling from interferon.
- Brand names
- Oxsoralen-Ultra
- Other names
- 8-MOP + interferonmethoxsalen + interferon8-methoxypsoralen plus interferon alfa-2a
02
Targets
ORM1 (Alpha-1-acid glycoprotein 1)DNAIFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on 8-methoxypsoralen + interferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 8-methoxypsoralen + interferon.